Journal of Bioequivalence & Bioavailability

Joel A Posener

Publications

• Research Article
  The Absolute Bioavailability of Desvenlafaxine in Healthy Subjects
  Author(s): Alice I Nichols, Jessica A Behrle, Lyette S Richards, Vernon D Parker, Joel A Posener, Richard Fruncillo and Jeffrey PaulAlice I Nichols, Jessica A Behrle, Lyette S Richards, Vernon D Parker, Joel A Posener, Richard Fruncillo and Jeffrey Paul
  
  Background and Objective: Desvenlafaxine (administered as desvenlafaxine succinate) is approved for the treatment of major depressive disorder (MDD). If eliminated by the kidney, desvenlafaxine may have more favorable pharmacokinetic or drug-drug interaction profiles compared to its parent compound, venlafaxine, which depends primarily on the CYP2D6 enzyme system. Therefore, the pharmacokinetics and bioavailability of desvenlafaxine was assessed in healthy human subjects. Methods: In a single-dose, open-label, crossover study, subjects were randomly assigned to 100 mg/d of oral desvenlafaxine or intravenous (50 mg/1 hr) desvenlafaxine. Plasma and urine were collected for 72 hours postdosing and assayed to determine pharmacokinetics and bioavailability of (R)-, (S)-, and (R+S)-desvenlafaxine and N,O-didesmethylvenlafaxine. Resul.. View More»
  DOI: 10.4172/jbb.1000105

  Abstract PDF